JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
(d) Election of New Director
On December15, 2016, the Board of Directors (the Board) of Jaguar
Animal Health,Inc. (the Company), by resolution as contemplated
in the Companys bylaws, increased the size of the Board from six
to seven directors. In connection therewith, and to fill the
newly created vacancy, the Board appointed Dr.Ari Azhir, age 69,
to serve as a ClassI director of the Company until the 2019
annual meeting of stockholders or until her successor is elected
and qualified. Dr.Azhir was also appointed by the Board to serve
as a member of the Audit Committee and the Compensation Committee
and Nominating Committee.
Accordingly, the current composition of the Boards committees is
as follows:
Audit Committee: Messrs.Bochnowski, Micek and Qiu,
Dr.Yang and Dr.Azhir
Compensation Committee: Messrs.Bochnowski, Kamphuis and
Micek and Dr.Azhir
Nominating Committee: Messrs.Bochnowski, Kamphuis and
Micek
Dr.Azhir is an entrepreneur and founder and CEO of two companies
focused on central nervous system (CNS) therapeutics: Neuraltus
Pharmaceuticals and Neurocea LLC. She has broad experience
launching and building life science companies and has
successfully commercialized and brought more than 20 healthcare
products to market, ranging from small molecule pharmaceuticals
for CNS and dermatology to disruptive technologies in medical
devices. These technologies include flow cytometry products at
Becton Dickinson and ultrasound devices at Accuson, where she
held executive management positions. Dr.Azhir has wide-ranging
drug development experience and has filed an NDA and gained
approval for Luxiq, a drug that has been successfully
commercialized. She also has extensive experience building strong
patent portfolios and is the key inventor and patent holder of 12
patents. She serves on the translational research board of UCSF
and has served on private boards (Polar Springs and Neuraltus),
as well as nonprofit boards (The Hearing Society and American
Women in Science).
Dr.Azhir received her B.SC in Biochemistry and Mathematics, as
well as her M.Ph. in Biophysics, from Kings College, London
University, and received a PhD. in Biophysics from Tehran
University.
On December19, 2016, the Company issued a press release with
respect to the foregoing, a copy of which is filed as Exhibit99.1
hereto.
In connection with Dr.Azhirs appointment to the Board and its
Committees, the Board, upon recommendation of the Compensation
Committee, granted Dr.Azhir options to purchase 98,050 shares of
the Companys common stock under its 2014 Stock Incentive Plan,
all of which vest monthly over 3-years such that they are vested
in full on the 3-year anniversary of the grant date, have an
exercise price of $0.74 per share, and expire 10-years from the
grant date.
Item9.01 Financial Statements and
Exhibits
(d)Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
Jaguar Animal Health,Inc. Press Release dated December19, |
About JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX)
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over nine indications across various species and non-prescription products targeting approximately seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Virend, Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm. Canalevia is its lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm Calf and Neonorm Foal are its lead non-prescription products to improve gut health and normalize stool formation. JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) Recent Trading Information
JAGUAR ANIMAL HEALTH, INC. (NASDAQ:JAGX) closed its last trading session down -0.050 at 0.690 with 263,144 shares trading hands.